Furthermore, screening for NAFLD and LF is recommended by the American Diabetes Association in patients diagnosed with T2DM which have elevated liver enzymes (ALT) or LS, while the American Association Society of Liver Disease is not in favour of routine screening in these patients [52, 53]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.